Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX): 55 pipeline candidates · 11 upcoming catalysts · ~34 mo cash runway · 25 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
34.0 months
D/E 0.27 · 0% dilution
Lead: Phase 3
55 candidates
11 upcoming, next in ~428d
N/A
A transparent, data-derived signal for Black Diamond Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$95.7M
Cash
$30.9M
Quarterly Burn
$10.2M
Runway
34.0 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (55 candidates)
| Drug | Phase |
|---|---|
| ABBV-155 | Phase 1 |
| ABBV-637 | Phase 1 |
| BDTX-1535 | Phase 2 |
| BDTX-4876 | Preclinical |
| BDTX-4933 | Phase 1 |
| Celecoxib | Phase 2 |
| Cytarabine | Phase 1 |
| Dinituximab | Phase 3 |
| Dinutuximab | Phase 3 |
| DOC1021 | Phase 2 |
Showing 10 of 55 candidates. Sign up for full pipeline.
Upcoming Catalysts (11)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
101
Total value held
$45.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,850,468 | $3.9M |
| renaissance technologies llc | 1,643,747 | $3.5M |
| dimensional fund advisors lp | 1,301,664 | $2.8M |
| blackrock, inc. | 1,106,840 | $2.4M |
| connor, clark & lunn investment management ltd. | 1,058,397 | $2.3M |
| mackenzie financial corp | 844,835 | $1.8M |
| marshall wace, llp | 836,266 | $1.8M |
| arrowstreet capital, limited partnership | 834,570 | $1.8M |
| bridgeway capital management, llc | 723,477 | $1.5M |
| goldman sachs group inc | 684,418 | $1.5M |
Showing top 10 of 101 institutional holders of Black Diamond Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Black Diamond Therapeutics, Inc.'s pipeline?
Black Diamond Therapeutics, Inc. (BDTX) has 55 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Black Diamond Therapeutics, Inc.'s lead drug candidate?
Black Diamond Therapeutics, Inc.'s most advanced tracked candidate is ABBV-155 (Phase 1) for Glioblastoma.
What is Black Diamond Therapeutics, Inc.'s next catalyst?
Black Diamond Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: FIBRICOR" — expected August 20, 2027.
What is Black Diamond Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Black Diamond Therapeutics, Inc. has approximately 34.0 months of cash runway.
What is Black Diamond Therapeutics, Inc.'s market capitalization?
Black Diamond Therapeutics, Inc.'s market capitalization is approximately $95.7M.
Get the full picture on Black Diamond Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.